Natera and Exelixis launched a collaboration for the STELLAR‑316 Phase 3 trial testing zanzalintinib, an oral kinase inhibitor, in MRD‑positive resected stage II/III colorectal cancer. Natera’s Signatera circulating tumor DNA MRD assay will select and monitor patients after definitive therapy, enabling enrollment of high‑risk patients without radiographic disease. Exelixis noted STELLAR‑316 will use disease‑free survival as the primary endpoint and will track ctDNA clearance as a secondary measure. The trial design reflects rising adoption of MRD‑guided adjuvant strategies and highlights diagnostics–drug partnerships to personalize cancer adjuvant therapy.